Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: – Stabilised eGFR, a key measure of kidney function – 71% of patients achieved zero C3c…